Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Freise

Showing results (101-110 of 121) with videos related to

Pageof 13
Sort By:
Journal of Veterinary Pharmacology and Therapeutics|June 27, 2012
The margin of safety of a single application of transdermal fentanyl solution when administered at multiples of the therapeutic dose to laboratory dogsM C Savides, R C Pohland, D A Wilkie, et al.
Journal of Veterinary Pharmacology and Therapeutics|December 19, 2013
The safety and effectiveness of a long-acting transdermal fentanyl solution compared with oxymorphone for the control of postoperative pain in dogs: a randomized, multicentered clinical studyS A Martinez, M G Wilson, D D Linton, et al.
Clinical Pharmacokinetics|September 18, 2016
Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic LeukemiaKevin J Freise, Aksana K Jones, Doerthe Eckert, et al.
Clinical Pharmacology and Therapeutics|April 13, 2007
Change in erythropoietin pharmacokinetics following hematopoietic transplantationJ A Widness, R L Schmidt, R J Hohl, et al.
Clinical Pharmacology and Therapeutics|August 5, 2020
Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic LeukemiaSathej Gopalakrishnan, William Wierda, Brenda Chyla, et al.
Journal of Veterinary Pharmacology and Therapeutics|November 10, 2007
Development and validation of the maximal electro-shock seizure model in dogsP R Territo, K J Freise, K Newhall, et al.
Expert Review of Anticancer Therapy|July 1, 2024
First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLCPierre Peterlin, Esma Saada-Bouzid, Mor Moskovitz, et al.
Transfusion|January 11, 2012
Comparison of red blood cell survival in sheep determined using red blood cells labeled with either biotin at multiple densities or [14C]cyanate: validation of a model to study human physiology and diseaseDonald M Mock, Nell I Matthews, Shan Zhu, et al.
Transfusion|June 22, 2010
Red blood cell (RBC) volume can be independently determined in vivo in the sheep using ovine RBCs labeled at different densities of biotinDonald M Mock, Nell I Matthews, Shan Zhu, et al.
Journal of Veterinary Pharmacology and Therapeutics|November 13, 2008
Nonlinear mixed effects pharmacokinetic/pharmacodynamic analysis of the anticonvulsant ameltolide (LY201116) in a canine seizure modelP R Territo, H E Shannon, K Newhall, et al.
Pageof 13

Showing results (101-110 of 121) with videos related to

Sort By:
Pageof 13
Journal of Veterinary Pharmacology and Therapeutics|June 27, 2012
The margin of safety of a single application of transdermal fentanyl solution when administered at multiples of the therapeutic dose to laboratory dogsM C Savides, R C Pohland, D A Wilkie, et al.
Journal of Veterinary Pharmacology and Therapeutics|December 19, 2013
The safety and effectiveness of a long-acting transdermal fentanyl solution compared with oxymorphone for the control of postoperative pain in dogs: a randomized, multicentered clinical studyS A Martinez, M G Wilson, D D Linton, et al.
Clinical Pharmacokinetics|September 18, 2016
Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic LeukemiaKevin J Freise, Aksana K Jones, Doerthe Eckert, et al.
Clinical Pharmacology and Therapeutics|April 13, 2007
Change in erythropoietin pharmacokinetics following hematopoietic transplantationJ A Widness, R L Schmidt, R J Hohl, et al.
Clinical Pharmacology and Therapeutics|August 5, 2020
Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic LeukemiaSathej Gopalakrishnan, William Wierda, Brenda Chyla, et al.
Journal of Veterinary Pharmacology and Therapeutics|November 10, 2007
Development and validation of the maximal electro-shock seizure model in dogsP R Territo, K J Freise, K Newhall, et al.
Expert Review of Anticancer Therapy|July 1, 2024
First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLCPierre Peterlin, Esma Saada-Bouzid, Mor Moskovitz, et al.
Transfusion|January 11, 2012
Comparison of red blood cell survival in sheep determined using red blood cells labeled with either biotin at multiple densities or [14C]cyanate: validation of a model to study human physiology and diseaseDonald M Mock, Nell I Matthews, Shan Zhu, et al.
Transfusion|June 22, 2010
Red blood cell (RBC) volume can be independently determined in vivo in the sheep using ovine RBCs labeled at different densities of biotinDonald M Mock, Nell I Matthews, Shan Zhu, et al.
Journal of Veterinary Pharmacology and Therapeutics|November 13, 2008
Nonlinear mixed effects pharmacokinetic/pharmacodynamic analysis of the anticonvulsant ameltolide (LY201116) in a canine seizure modelP R Territo, H E Shannon, K Newhall, et al.
Pageof 13